Predi-COVID aims to identify important risk factors and biomarkers associated with the severity of Covid-19 and the long-term health consequences of the disease in Luxembourg. The study also includes household members of Covid-19 positive participants to study the transmission of the virus in this high-risk population.
A cohort of more than 200Covid-19 positive participants over 18 years of age was established with those newly tested positive who agreed to share their data for research purposes. Predi-COVID consists in the collection of clinical data and associated biological samples to better characterise symptoms and clearly define the different outcomes of the disease. Several biological samples - including blood, nasal and oral swabs, saliva and stool - are collected from participants to identify human and viral predictive markers.
The evolution of the health and symptoms of enrolled participants are followed daily by various remote digital tools for 14 days. Short additional assessments are also conducted monthly for up to 12 months to evaluate the potential long-term consequences of Covid-19 disease.
Finally, voice recordings from Covid-19 participants are also collected through a smartphone application called CoLive. This digital voice data will allow researchers to identify "voice biomarkers" of symptoms frequently observed in patient with Covid-19 disease. This may help identify signs of respiratory syndromes, fatigue, anxiety or negative emotions related to Covid-19, which could then be used for remote monitoring of Covid-19 patients at home.
The “Predi-COVID” study is led by a consortium of Luxembourgish research institutions, including Luxembourg Institute of Health (LIH), Integrated Biobank of Luxembourg (IBBL), the Laboratoire National de Santé (LNS), the University of Luxembourg, the Luxembourg Centre for Systems Biomedicine (LCSB), the Centre Hospitalier de Luxembourg (CHL) and the Hôpitaux Robert Schuman (HRS).
The study is co-financed by the Luxembourg National Research Fund (FNR) and supported by André Losch Foundation.
Guy FAGHERAZZI, PhD
1 AB rue Thomas Edison